AKR30 Jun 2011 08:06
US$3.2 Million Purchase Order - Revelar Free Radical Assay
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, has secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar breath tubes to Pulse Health, LLC under the Company's Supply Agreement, as announced on 11 April 2011. This is the first purchase order under the Supply Agreement and manufacturing will commence immediately, from ABI's New Jersey facility, with the majority of this order expected to be fulfilled during 2011.
Revelar provides the first accurate measurement system that both detects and measures aldehydes in exhaled breath. Aldehydes are known to be indicators of free radical activity that are thought to negatively impact or damage healthy cells throughout the human body. External factors, such as diet, activity, stress, chemicals and pollutants cause the body to produce excess free radicals that damage healthy cells. Studies show this may lead to heart disease, cancer and rapid aging.
Millions of people in the developed world are consuming antioxidant supplements to counteract this process but neither patients, nor healthcare practitioners, have previously been able to accurately and efficiently determine whether a regime is working to improve patient health. The Revelar Assay, which consists of an electronic analyser and disposable breath tubes, instantly measures a patient's baseline aldehyde level and provides a numerical score, providing the first rapid, non-invasive way to measure the effectiveness of an antioxidant regimen and other interventions.
Pulse Health, LLC, based in Portland, Oregon, is supplying The Revelar Assay to healthcare practitioners - particularly chiropractic centres - and health supplement producers and distributors initially in the USA and throughout the EU and then worldwide, where the sale of antioxidant products represents a multi-billion dollar annual market.